Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cardiovasc Intervent Radiol. 2021 Sep;44(9):1355-1366. doi: 10.1007/s00270-021-02877-3. Epub 2021 Jun 17.
This systematic review was conducted to determine factors that are associated with the degree of hypertrophy of the future liver remnant following portal vein embolization. An extensive search on September 15, 2020, and subsequent literature screening resulted in the inclusion of forty-eight articles with 3368 patients in qualitative analysis, of which 18 studies were included in quantitative synthesis. Meta-analyses based on a limited number of studies showed an increase in hypertrophy response when additional embolization of segment 4 was performed (pooled difference of medians = - 3.47, 95% CI - 5.51 to - 1.43) and the use of N-butyl cyanoacrylate for portal vein embolization induced more hypertrophy than polyvinyl alcohol (pooled standardized mean difference (SMD) = 0.60, 95% CI 0.30 to 0.91). There was no indication of a difference in degree of hypertrophy between patients who received neo-adjuvant chemotherapy and those who did not receive pre-procedural systemic therapy(pooled SMD = - 0.37, 95% CI - 1.35 to 0.61), or between male and female patients (pooled SMD = 0.19, 95% CI - 0.12 to 0.50).The study was registered in the International Prospective Register of Systematic Reviews on April 28, 2020 (CRD42020175708).
本系统评价旨在确定与门静脉栓塞后剩余肝未来肥大程度相关的因素。2020 年 9 月 15 日进行了广泛的搜索,随后进行了文献筛选,纳入了 48 篇包含 3368 例患者的定性分析文章,其中 18 项研究纳入了定量综合分析。基于少数研究的荟萃分析显示,当额外栓塞 4 段时,肥大反应增加(中位数的合并差异=-3.47,95%CI-5.51 至-1.43),并且使用 N-丁基氰基丙烯酸酯进行门静脉栓塞诱导的肥大比使用聚乙烯醇(合并标准化均数差(SMD)=0.60,95%CI0.30 至 0.91)更明显。接受新辅助化疗和未接受术前系统治疗的患者之间(合并 SMD=-0.37,95%CI-1.35 至 0.61),或男性和女性患者之间(合并 SMD=0.19,95%CI-0.12 至 0.50),其肥大程度没有差异。该研究于 2020 年 4 月 28 日在国际系统评价前瞻性注册库(CRD42020175708)中进行了注册。